# A Registry Study of NanoKnife IRE for Stage 3 Pancreatic Cancer

> **NCT03899649** · — · ACTIVE_NOT_RECRUITING · sponsor: **Angiodynamics, Inc.** · enrollment: 532 (estimated)

## Conditions studied

- Stage III Pancreatic Cancer

## Interventions

- **DRUG:** SOC
- **DEVICE:** NanoKnife System

## Key facts

- **NCT ID:** NCT03899649
- **Lead sponsor:** Angiodynamics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-05-08
- **Primary completion:** 2025-04
- **Final completion:** 2025-04
- **Target enrollment:** 532 (ESTIMATED)
- **Last updated:** 2025-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03899649

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03899649, "A Registry Study of NanoKnife IRE for Stage 3 Pancreatic Cancer". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT03899649. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*